CTRI/2025/08/093411
Recruiting
Phase 3
An Open- Label, Multicenter, Phase III Clinical Study in India to Evaluate the Efficacy and Safety of Human Normal Immunoglobulin for Intravenous use (IVIG) in Chronic Immune Thrombocytopenia (ITP)
Bharat Serums and Vaccines Ltd8 sites in 1 country30 target enrollmentStarted: September 1, 2025Last updated:
Overview
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Bharat Serums and Vaccines Ltd
- Enrollment
- 30
- Locations
- 8
- Primary Endpoint
- The number and percentage of subjects with response (R).
Overview
Brief Summary
This is an open-label, multicenter, Phase III clinical study to evaluate the efficacy and safety of IVIG in Indian adult Subjects with immune thrombocytopenia (ITP). Eligible adult subjects with chronic ITP will be enrolled in the study. Subjects will receive IVIG, and the efficacy and safety parameters will be assessed at specified intervals up to day 28. All the outcome measures will be assessed until the end of the study visit (day 28).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Masking
- None
Eligibility Criteria
- Ages
- 18.00 Year(s) to 99.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Confirmed diagnosis of Chronic ITP of atleast 12 months duration Platelet count more than 30,000 per mm3 at screening.
- •absence of other conditions that could cause thrombocytopenia.
- •If subjects are currently being treated with corticosteroids the treatment regimen or dose must have been stable.
- •if subjects are currently being created with cyclophosphamide, azathioprine or attenuated androgens the treatment regimen and dose must have been stable.
- •Splenectomized subjects and both RhD positive and Rh-D negative subject can be included.
- •if subect is a female of child-bearing potential, she must have a negative result on urine-based human chorionic gonadotropin pregnancy test.
- •if subject is a female who is or becomes sexually active, she must practice contraception by using a method of proven reliability for the duration of the study.
Exclusion Criteria
- •Subect has history of any severe or anaphylactic reaction to IVIG or any other IgG preparation or its excipients.
- •Subject has received an IVIG preparation within 1 month prior to screening.
- •Received any blood, blood product, or blood derivative within the 1 month before screening.
- •Received Rituximab within the 3 months before screening.
- •Subject is pregnant or is in a period of lactation Subject has a severe renal impairment Subject is known to have abused alcohol, opiates, psychotropic agents, or other chemicals or drugs with abuse potential in the past 12 months.
- •Subject has a history of deep vein thrombosis (DVT) or thrombotic complications of IVIG therapy subject has any history or sign of hyperviscosity, transient ischemic attack (TIA), stroke, other thromboembolic event, or unstable angina Subject suffers from any acute or chronic medical conditions that may interfere with the conduct of study.
Outcomes
Primary Outcomes
The number and percentage of subjects with response (R).
Time Frame: up to day 28
Secondary Outcomes
- The number and percentage of subjects with CR, LR, and NR(up to day 28)
- Time (in days) from treatment to R(up to day 28)
- Time (in days) from treatment to CR(up to day 28)
- Duration (in days) of R(up to day 28)
- Duration (in days) of CR(up to day 28)
Investigators
Dr Ramesh Jagannathan
Bharat serums and Vaccines LTd
Study Sites (8)
Loading locations...
Similar Trials
Not yet recruiting
Phase 3
SYS6010 Versus Docetaxel for Previously Treated EGFR Wild-type NSCLC: Phase ⅢNCT07442565CSPC Megalith Biopharmaceutical Co.,Ltd.506
Not yet recruiting
Phase 1
EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell LymphomasNCT07339527Sun Yat-sen University60
Recruiting
Phase 1
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerNCT07281976Nanjing Leads Biolabs Co.,Ltd220
Not yet recruiting
Phase 1
A Clinical Study of ZL-85FA TabletsNCT07339748Chengdu Zenitar Biomedical Technology Co., Ltd51
Not yet recruiting
Not Applicable
A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular CarcinomaNCT07309419Shanghai Zhongshan Hospital222